Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N4-methylthiosemicarbazone)

Journal of Nuclear Medicine

Volumn 43, Issue 11, 2002, Pages 1557-1569

  Lewis, Jason S ^a   Herrero, Pilar ^a   Sharp, Terry L ^a   Engelbach, John A ^a   Fujibayashi, Yasuhisa ^a   Laforest, Richard ^a   Kovacs, Attila ^a   Gropler, Robert J ^a   Welch, Michael J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Copper(II) diacetyl bis(N4 methylthiosemicarbazone); Hypoxia; Imaging(ischemia

Indexed keywords

COPPER 60; COPPER 61; COPPER 64; COPPER DERIVATIVE; COPPER DIACETYL BIS(4 N METHYLTHIOSEMICARBAZONE); DOBUTAMINE; THIOSEMICARBAZONE DERIVATIVE; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DOG; HEART MUSCLE BLOOD FLOW; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ANIMALS; ANOXIA; CELL HYPOXIA; COPPER RADIOISOTOPES; CORONARY CIRCULATION; DOGS; HEART; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIUM; ORGANOMETALLIC COMPOUNDS; OXYGEN; THIOSEMICARBAZONES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036841704     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Chapman JD, Zanzonico P, Ling CC. On measuring hypoxia in individual tumors with radiolabeled agents. J Nucl Med. 2001;42:1653-1655.
2. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med. 1995;22:265-280.
3. 123I-iodoazomycin arabinoside: Preliminary report of a clinical study. Br J Cancer, 1992;65:90-95.
4. Grosher D, McEwan AJB, Parliament MB, et al. Imaging tumor hypoxia and tumor perfusion. J Nucl Med. 1993;34:885-888.
5. Okada RD, Johnson G, Nguyen KN, et al. "Hot spot" detection of ischemic myocardium in vivo by gamma camera imaging. Circulation. 1998;97:2557-2566.
6. Ng CK, Sinusas AJ, Zaret B, Souter R. Kinetic analysis of technetium-99m-labeled nitroimidazole (BMS181321) as a tracer of myocardial hypoxia. Circulation. 1995;92:1261-1268.
7. Wedeking P, Yost F, Wen M, et al. Comparison of the biological activity of the isomers of the Tc-99m-nitroimidazole complex BMS-194796 [abstract]. J Nucl Med. 1995;36(suppl):17P.
8. Shelton ME, Dence C, Hwang D-R, Welch MJ, Bergmann SR. Myocardial kinetics of fluorine-18 misonidazole: A marker of hypoxic myocardium. J Nucl Med. 1989;30:351-358.
9. Martin GV, Caldwell JH, Graham MM, et al. Non-invasive detection of hypoxic myocardium using flourine-18-fluoromisonidazole and positron emission tomography. J Nucl Med. 1992;33:2202-2208.
10. Shelton ME, Dence CS, Hwang D-R, Herrero P, Welch MJ, Bergmann SR. In vivo delineation of myocardial hypoxia during coronary occlusion using fluorine-18 fluoromisonidazole and positron emission tomography: A potential approach for identification of jeopardized myocardium. J Am Coll Cardiol. 1990; 16:477-485.
11. 3H]fluoromisonidazole in ischemic myocardium. J Nucl Med. 1989;30:194-201.
12. 4-methylthiosemicarbazone). Nucl Med Biol. 1987;14:59-61.
13. 4-methylthiosemicarbazonato)copper(II): Synthesis and evaluation as a positron emission tomography tracer for cerebral and myocardial perfusion. J Nucl Med. 1990;31:1989-1996.
14. 64Cu-ATSM in vivo and in vitro in a hypoxic tumor model. J Nucl Med. 1999;40:177-183.
15. Dearling JLJ, Lewis JS, Mullen GED, Welch MJ, Blower MJ. Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: Structure-activity relationships. J Biol Inorg Chem. 2002;7:249-259.
16. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: A new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155-1160.
17. Fujibayashi Y, Cutler CS, Anderson CJ, et al. Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: Ex vivo imaging of hypoxia in rats. Nucl Med Biol. 1999;26:117-121.
18. 4-methylthiosemicarbazone): effect of changes in tissue oxygenation. J Nucl Med. 2001:42:655-661.
19. Takahashi N, Fujibayashi Y, Yonekura Y, et al. Copper-62 ATSM as a hypoxic tracer in myocardial ischemia. Ann Nucl Med. 2001;15:293-296.
20. 64Cu using a biomedical cyclotron. Nucl Med Biol. 1997;24:35-43.
21. McCarthy DW, Bass LA, Cutler PD. et al. High purity production and potential applications of copper-60 and copper-61. Nucl Med Biol. 1999;26:351-358.
22. 62Cu-PTSM. J Nucl Med. 2000;41:309-314.
23. Derenzo SE, Budinger TF, Juesman RH, Cahoon JL, Vuletich T. Imaging properties of a positron tomograph with 280 BGO crystals. IEEE Trans Nucl Sci. 1981;NS-28:81-99.
24. Bredle DL, Chapler CK, Cain SM. Metabolic and circulatory responses of normoxic skeletal muscle to whole-body hypoxia. J Appl Physiol. 1988;65:2063-2068.
25. Bergmann SR, Lerch RA, Fox KAA, et al. Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography. Am J Med. 1982;73:573-581.
26. Fishbein MC, Meerbaum S, Rit J, et al. Early phase acute myocardial infarct size quantification: Validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J. 1981;101:593-600.
27. Kloner RA, Darsee JR, DeBoer LWV, Carlson N. Early pathologic detection of acute myocardial infarction. Arch Pathol Lab Med. 1981;105:403-406.
28. 15O and positron-emission tomography. Circulation. 1985;71:1271-1278.
29. 62Cu-PTSM and positron emission tomography. Circulation. 1993;87:173-183.
30. 15O and positron emission tomography: Assessment and error analysis of a mathematical approach. J Comput Assist Tomogr. 1989;13:862-873.
31. National Nuclear Data Center, Brookhaven National Laboratory. Nuclear Decay Data in the MIRD Format. Available at: http://www.nndc.bnl.gov/nndc/formmird.html. Accessed August 22, 2002.
32. Chao C, Bosch WR, Mutic S, et al. A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Biol Phys. 2001;49:1171-1182.
33. Dehdashti F, Mintun MA, Lewis JS, Govindan R, Welch MJ. Evaluation of tumor hypoxia with Cu-60-ATSM and PET [abstract]. J Nucl Med. 2000; 41(suppl):34P.
34. McCarthy DW, Bigott HM, Perkins TA, Voller TF, Welch MJ. A research resource in radionuclide research. J Labelled Compds Radiopharm. 2001;44: S817-S819.
35. Fujibayashi Y, Matsumoto K, Yonekura Y, Konishi J, Yokoyama A. A new zinc-62/copper-62 generator as a copper-62 source for PET radiopharmaceuticals. J Nucl Med. 1989;30:1838-1842.
36. Robinson JGD, Zielinski FW, Lee AW. The zinc-62/copper-62 generator: A convenient source of copper-62 for radiopharmaceuticals. Int J Appl Radiat Isot. 1980:31:111-116.
37. Rumsey WL, Patel B, Linder K. Effect of graded hypoxia in retention of technetium-99m-nitroheterocycle in perfused rat hearts. J Nucl Med. 1995;36:632-636.
38. Rumsey WL, Patel B, Kuczynski B, et al. Comparison of two novel technetium agents for imaging ischemic myocardium [abstract]. Circulation. 1995;92(suppl): 1-181.
39. Cook GJR, Houston S, Barrington SF, Fogelman I. Technetium-99m-labeled HL91 to identify tumor hypoxia: Correlation with fluorine-18-FDG. J Nucl Med. 1998;39:99-103.
40. Okada RD, Johnson G, Nguyen KN, Carlson LR, Beju D. HL-91-technetium-99m: A new marker of viability in ischemic myocardium. J Nucl Cardiol. 1999;6:306-315.